Portfolio — seedfolio

ACQUIRED. Improving lower pelvic surgeries with faster safer ureter identification

AmplifiDx: Faster and 10x cheaper than PCR. The next point-of-care molecular diagnostics platform.

Amplo is treating diseases of the neuro-muscular junction (including congenital myasthenia syndrome, ALS, and muscular dystrophies) by one-time Dok7-gene therapy

Anvil uses existing ultrasensitive dPCR, but tricks it out to turn 6 channels into 63 for specific-pathogen identification. Sepsis path ID in 2 hours at POC instead of 2 days by culture.

BobcatBio is advancing macrophage-based cell therapies for the treatment of solid tumors

Duo Oncology has novel polymeric micelles small enough (15nm) to penetrate stroma in tumors (like pancreatic) and deliver proven payloads.

Earthgrid has “groundbreaking” tunnel-boring technology to allow renewable projects to more easily connect to the grid.

eGlint has a novel detection approach to leverage aptamers for fast, low-cost, high-accuracy, high-multiplex diagnostics

Ekefalos is developing cyclotides to deliver proteins (enzymes, antibodies, growth factors) across the blood brain barrier

Portable solar/battery towers for lights/comms/security, with no tow-hitch needed. Elegant design. Compact package. Industrial ruggedness. For construction, military/first-responders, sports, and events.

HDAX Therapeutics has potent, bitopic-binding small molecule inhibitors of HDAC6 for neurologic (CMT, CIPN, ALS) and cardiovascular indications.

Hervolution has a novel cancer vaccine targeting human endogenous retrovirus

Himalaya Therapeutics has xclusive access in China to BioAtla’s “CAB” therapeutics to treat cancer

Illudent is advancing a novel small molecule as a precision medicine for solid tumors

Innova Vascular has FDA-cleared minimally invasive devices that retrieve and aspirate clots in legs (DVT) or lungs (PE).

Ivy Energy provides an “Easy Button” for landlords to leverage VNEM to profitably add solar to their apartments.

Life Detection Technologies prevents hospitalization by predicting COPD exacerbations through non-contact overnight monitoring of heart and respiration rates.

Lilium has achieved the trifecta of in-vivo gene delivery (cell-specific targeting, no liver sink, no immunogenicity)

Maxwell Biomedical is developing an electronic implantable device to correct atrial fibrillation

Myogenica is advancing progenitor muscle stem cells to treat muscular dystrophies.

NanoPharma Solutions increases the solubility of drugs without solvents or stabilizers. Great for intranasal and inhalable formulations.

Novel Biotechnology manufactures DNA plasmids using a proprietary bacterial strain. A drop-in replacement for e. coli, it can produce challenging plasmids at higher yield in less time.

Ordaos has a best-in-class team and AI system to generate mini proteins. Compared to typical antibody screening, they deliver leads with 1000x more affinity in 1/10th the time.

Particella has novel lipid nanoparticles for ORAL delivery of mRNA to the intestine

Palm Therapeutics has developed a novel, rapid screening system to find protein-specific inhibitors of palmitoylation. First target is pan-NRAS-mutant cancers.

PercAssist is developing the first minimally invasive heart-assist device

Progentos is developing a small molecule to reverse the course of multiple sclerosis.

Pulmair is developing stents for lungs to keep airways open

Pyrojas is developing personalized, durable, effective cancer vaccines—with a twist. They isolate a patient’s cancer cells, genetically and chemically modify them, and reinject them into the patient.

ACUIRED by Intuitive Surgical. Ruby has Robotics and AI to autonomously prepare, image and assess tissue during biopsy procedures

RecoverX has AI (without hallucinations) for differntial diagnosis at point of care, based on ground truth like JAMA and BMJ, helping clinicians make better faster diagnoses

Regenosine delivers natural adenosine to regrow cartilage to reverse arthritis.

Remedium has developed a novel gene therapy delivery platform. They load DNA into proprietary LNPs, inject those subcutaneously, and turn fat cells into protein factories. For just one example: a single injection to produce stable GLP1 for 3+ years. Unique among gene therapies, they can later adjust the dose up or DOWN.

Renovo Rx is in Phase 3 trials of their drug-device combo that delivers chemo to a tumor site via a minimally invasive catheter. Interim results show a doubling of PFS and reduced toxicity in locally advanced pancreatic cancer.